Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Tagrisso Faces 10.5% Slash in June in Its Second Re-Pricing
March 9, 2023
- Emgality, Veklury, and More to Get Lower Prices in June: CEA Scheme
March 9, 2023
- LDP League Delivers Proposal on Health Coverage for Patches to Finance Minister
March 9, 2023
- Expert Narukawa Backs JPMA Pitch on Value-Based Pricing, but Disputes Blanket Price Maintenance for Patented Meds
March 8, 2023
- Japan Starts Omicron Vaccine Rollout for Ages 5-11
March 8, 2023
- Japan Panel OKs 2-Dose Regimen for Silgard 9 for Girls below Age 15
March 8, 2023
- AbbVie’s ADC Bags Sakigake Designation in Japan
March 8, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
- Japan to Lead Discussions on AMR Measures at G7 Summit: PM
March 7, 2023
- Eli Lilly’s UC Drug Mirikizumab in Line for Approval as Early as March
March 6, 2023
- MHLW Calls for Fair-Price Distribution of Drugs Subject to Unprofitability Re-Pricing
March 6, 2023
- SCARDA to Invite Funding Applications for New Modality Research without Requiring PI Plans
March 3, 2023
- LDP Taskforce Begins Social Security Debates towards Honebuto
March 3, 2023
- MHLW Unveils New List Prices for FY2023 Revision, Ad-Hoc PMP Raise for 143 Products
March 3, 2023
- Komeito Petitions Govt for Market Incentives for Meiji’s Novel Antibacterial
March 2, 2023
- LDP League to Compile Final Proposal for SaMD Reimbursement This Spring
March 2, 2023
- Shelf Life of Ronapreve, Xevudy Extended to 30 Months in Japan
March 1, 2023
- Japan Panel Backs Approval of 1st Nasal Flu Vaccine
February 28, 2023
- Pfizer’s Omicron-Adapted Jab for Ages 5-11 in Line for Japan Approval
February 28, 2023
- Nipro Pharma Told to Improve Biz over Violations Spanning 42 Products, Faked Records
February 27, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…